In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients
- 1 January 1987
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 31 (1) , 102-103
- https://doi.org/10.1128/aac.31.1.102
Abstract
The in vitro activity of S-25930 and S-25932, two new 4-quinolones, against 450 aerobic gram-negative organisms isolated from cancer patients was evaluated and compared with the activity of ciprofloxacin, enoxacin, difloxacin (A-56619), and A-56620. Both agents inhibited most members of the family Enterobacteriaceae at concentrations of less than or equal to 2.0 micrograms/ml, but their activity against Pseudomonas aeruginosa was inferior to that of other quinolones. Although considerably less active than ciprofloxacin and A-56620, S-25930 was frequently two- to eightfold more active than S-25932 and was comparable to difloxacin and enoxacin against most isolates.This publication has 5 references indexed in Scilit:
- In vitro activity of BRL 36650, a new semisynthetic penicillinAntimicrobial Agents and Chemotherapy, 1986
- In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620Antimicrobial Agents and Chemotherapy, 1985
- Acinetobacter calcoaceticus Septicemia in Patients With CancerSouthern Medical Journal, 1985
- Bacteremia Caused By Aeromonas Species in Hospitalized Cancer PatientsClinical Infectious Diseases, 1985
- Antibiotics in patients with neutropenia.1984